LONDON, ONTARIO and BOSTON, MASSACHUSETTS–(Marketwired – Dec. 6, 2017) – Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) (“COTI” or a “Company“), a clinical theatre biopharmaceutical association advancing a tube of targeted therapies for a diagnosis of cancer, currently announced a change in a formerly set date for a Company’s Annual and Special Meeting of Shareholders (the “Meeting“), that was creatively scheduled for Thursday, Dec 7, 2017 during 9:30 a.m. Eastern Standard Time.
The AGM will now be hold on Wednesday, Dec 20, 2017 during 9:30 a.m. EST during The London Club, Grand Ballroom, 177 Queens Avenue, London, Ontario, N6A 1J1. The record date for last shareholders entitled to accept notice of and opinion during a Meeting stays unchanged.
About Critical Outcome Technologies Inc.
Critical Outcome Technologies is a clinical theatre biotech association that uses exclusive synthetic comprehension technologies to pursue a targeted and transformational proceed to treating cancer and other unmet medical needs. COTI’s CHEMSAS® record accelerates a find and growth of novel drug therapies, permitting a Company to build a tube of intensity drug possibilities faster and with a aloft luck of success than normal methods.
The Company’s lead compound, COTI-2, has a novel p53-dependent resource of movement with resourceful and manly anti-cancer activity. P53 mutations start in over 50% of all cancers. COTI-2 is primarily being evaluated for a diagnosis of gynecologic cancers and conduct and neck squamous dungeon carcinoma in a Phase 1 clinical hearing during a MD Anderson Cancer Center during a University of Texas and a Lurie Cancer Center during Northwestern University. The Company has cumulative waif drug standing in a United States for COTI-2 for a diagnosis of ovarian cancer. Preclinical information suggests that COTI-2 could dramatically urge a diagnosis of cancers with mutations in a p53 gene.
The Company’s second lead compound, COTI-219, is a novel verbal tiny proton devalue targeting a mutant forms of KRAS but stopping normal KRAS function. KRAS mutations start in adult to 30% of all cancers and paint a extensive unmet clinical need and a fascinating drug target. COTI-219 is undergoing IND-enabling studies to support a regulatory acquiescence in early 2018.
Follow @CriticalOutcome on Twitter during http://twitter.com/CriticalOutcome
Neither a TSX Venture Exchange nor a Regulation Services Provider (as that tenure is tangible in policies of a TSX Venture Exchange) accepts shortcoming for a endowment or correctness of this release.
For some-more information, revisit www.criticaloutcome.com.